No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Takeda Pharmaceuticals Releases Long term results of IV SC Vedolizumab Switching Study
On 26 February 2024, the results of an 18 month study sponsored by Takeda Pharmaceuticals were published in Crohn's & Colitis 360. The study involved 108 patients switched from IV to a subcutaneous vedolizumab. The results of the study suggested that switching...